Phase I Trial to Compare Pharmacokinetics and Safety of SYP-0704A With Taxotere in Subjects With Advanced Solid Tumor
Comparison of pharmacokinetic parameters (T1/2β, CL, Vdss) Safety as measured by adverse
events
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Pharmacokinetics of SYP-0704A and Taxotere in terms of AUC
3 months
No
Shin je gook, doctor
Principal Investigator
Inje Pusan Paik university hospital
Korea: Food and Drug Administration
DOCXN101
NCT01336582
August 2009
August 2012
Name | Location |
---|